Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00616733 · ClinicalTrials.gov registry record · Phase 1

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

A Phase 1 study of Multiple Sclerosis, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
5
Study locations

NCT00616733 is a Phase 1 study of Multiple Sclerosis that has completed, run by Daiichi Sankyo. The registered enrollment target is 25 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00616733, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
5
Study locations

Study Summary

This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

Conditions Studied

Multiple Sclerosis

Interventions

  • DRUG CS-0777 tablets

Study Locations (5)

Colorado

  • - Denver

Florida

  • - Port Orange

Kansas

  • - Lenexa

Montana

  • - Billings

Pennsylvania

  • - Philadelphia

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2008-03
Est. Completion 2010-09
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00616733

The ClinicalTrials.gov registry entry for NCT00616733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which CS-0777 tablets is the first listed.

NCT00616733 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT00616733 about?

NCT00616733 is a clinical study titled "12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients". This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

What is the current status of trial NCT00616733?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2010-09.

What conditions does trial NCT00616733 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT00616733?

The interventions under investigation include: CS-0777 tablets (DRUG).

Who is sponsoring clinical trial NCT00616733?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00616733 being conducted?

This trial has 5 study locations across Colorado, Florida, Kansas, Montana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.